Innate Pharma SA

Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
  • TickerIPH
  • ISINFR0010331421
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance
IPH Innate Pharma S... (Health Care)

Innate Pharma: 1 director

A director at Innate Pharma sold 10,000 shares at 5.500EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Olga Smolentseva
  • Olga Smolentseva
IPH Innate Pharma S... (Health Care)

Update INNATE PHARMA BUY – TP EUR12 vs. 6.4 Monalizumab smiles again

Update INNATE PHARMA BUY – TP EUR12 vs. 6.4 Monalizumab smiles again Innate Pharma’s equity story received a significant boost of confidence on the back of ESMO 2021, with the presentation of its ANKET platform, but most remarkably – monalizumab’s success in combination with AstraZeneca’s anti-PD-L1, durvalumab (Imfinzi), as a maintenance therapy for stage III NSCLC. Recall, Monalizumab is being developed in collaboration with AZ and the amendment of the expected milestone payment left investors doubting AZ’s confidence in this programme. At ESMO 2021, AZ presented impressive interim res...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Number of Shares and Voting Rights of Innate Pharma as of September 1,...

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 MARSEILLE, France, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021: Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferred Shares 20...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er s...

Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er septembre 2021 Marseille, 23 sept. 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 1er septembre 2021 :          Nombre d’actions composant le capital :79 294 402 actions ordinaires 6 784 Actions de Préférence 2016 ...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Number of Shares and Voting Rights of Innate Pharma as of September 1,...

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021:   Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferred Shares 2016 7...

IPH Innate Pharma S... (Health Care)

Innate Pharma: 1 director

A director at Innate Pharma sold 10,000 shares at 5.500EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Olga Smolentseva
  • Olga Smolentseva
IPH Innate Pharma S... (Health Care)

Update INNATE PHARMA BUY – TP EUR12 vs. 6.4 Monalizumab smiles again

Update INNATE PHARMA BUY – TP EUR12 vs. 6.4 Monalizumab smiles again Innate Pharma’s equity story received a significant boost of confidence on the back of ESMO 2021, with the presentation of its ANKET platform, but most remarkably – monalizumab’s success in combination with AstraZeneca’s anti-PD-L1, durvalumab (Imfinzi), as a maintenance therapy for stage III NSCLC. Recall, Monalizumab is being developed in collaboration with AZ and the amendment of the expected milestone payment left investors doubting AZ’s confidence in this programme. At ESMO 2021, AZ presented impressive interim res...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Number of Shares and Voting Rights of Innate Pharma as of September 1,...

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 MARSEILLE, France, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021: Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferred Shares 20...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er s...

Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er septembre 2021 Marseille, 23 sept. 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 1er septembre 2021 :          Nombre d’actions composant le capital :79 294 402 actions ordinaires 6 784 Actions de Préférence 2016 ...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Number of Shares and Voting Rights of Innate Pharma as of September 1,...

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021:   Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferred Shares 2016 7...

IPH Innate Pharma S... (Health Care)

Innate Pharma: 1 director

A director at Innate Pharma sold 10,000 shares at 5.500EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Olga Smolentseva
  • Olga Smolentseva
IPH Innate Pharma S... (Health Care)

Update INNATE PHARMA BUY – TP EUR12 vs. 6.4 Monalizumab smiles again

Update INNATE PHARMA BUY – TP EUR12 vs. 6.4 Monalizumab smiles again Innate Pharma’s equity story received a significant boost of confidence on the back of ESMO 2021, with the presentation of its ANKET platform, but most remarkably – monalizumab’s success in combination with AstraZeneca’s anti-PD-L1, durvalumab (Imfinzi), as a maintenance therapy for stage III NSCLC. Recall, Monalizumab is being developed in collaboration with AZ and the amendment of the expected milestone payment left investors doubting AZ’s confidence in this programme. At ESMO 2021, AZ presented impressive interim res...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Number of Shares and Voting Rights of Innate Pharma as of September 1,...

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 MARSEILLE, France, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021: Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferred Shares 20...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er s...

Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er septembre 2021 Marseille, 23 sept. 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 1er septembre 2021 :          Nombre d’actions composant le capital :79 294 402 actions ordinaires 6 784 Actions de Préférence 2016 ...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Number of Shares and Voting Rights of Innate Pharma as of September 1,...

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021:   Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferred Shares 2016 7...

IPH Innate Pharma S... (Health Care)

Innate Pharma: 1 director

A director at Innate Pharma sold 10,000 shares at 5.500EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Olga Smolentseva
  • Olga Smolentseva
IPH Innate Pharma S... (Health Care)

Update INNATE PHARMA BUY – TP EUR12 vs. 6.4 Monalizumab smiles again

Update INNATE PHARMA BUY – TP EUR12 vs. 6.4 Monalizumab smiles again Innate Pharma’s equity story received a significant boost of confidence on the back of ESMO 2021, with the presentation of its ANKET platform, but most remarkably – monalizumab’s success in combination with AstraZeneca’s anti-PD-L1, durvalumab (Imfinzi), as a maintenance therapy for stage III NSCLC. Recall, Monalizumab is being developed in collaboration with AZ and the amendment of the expected milestone payment left investors doubting AZ’s confidence in this programme. At ESMO 2021, AZ presented impressive interim res...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Number of Shares and Voting Rights of Innate Pharma as of September 1,...

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 MARSEILLE, France, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021: Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferred Shares 20...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er s...

Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er septembre 2021 Marseille, 23 sept. 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 1er septembre 2021 :          Nombre d’actions composant le capital :79 294 402 actions ordinaires 6 784 Actions de Préférence 2016 ...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Number of Shares and Voting Rights of Innate Pharma as of September 1,...

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021:   Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferred Shares 2016 7...

IPH Innate Pharma S... (Health Care)

Innate Pharma: 1 director

A director at Innate Pharma sold 10,000 shares at 5.500EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Olga Smolentseva
  • Olga Smolentseva
IPH Innate Pharma S... (Health Care)

Update INNATE PHARMA BUY – TP EUR12 vs. 6.4 Monalizumab smiles again

Update INNATE PHARMA BUY – TP EUR12 vs. 6.4 Monalizumab smiles again Innate Pharma’s equity story received a significant boost of confidence on the back of ESMO 2021, with the presentation of its ANKET platform, but most remarkably – monalizumab’s success in combination with AstraZeneca’s anti-PD-L1, durvalumab (Imfinzi), as a maintenance therapy for stage III NSCLC. Recall, Monalizumab is being developed in collaboration with AZ and the amendment of the expected milestone payment left investors doubting AZ’s confidence in this programme. At ESMO 2021, AZ presented impressive interim res...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Number of Shares and Voting Rights of Innate Pharma as of September 1,...

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 MARSEILLE, France, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021: Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferred Shares 20...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er s...

Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er septembre 2021 Marseille, 23 sept. 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 1er septembre 2021 :          Nombre d’actions composant le capital :79 294 402 actions ordinaires 6 784 Actions de Préférence 2016 ...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Number of Shares and Voting Rights of Innate Pharma as of September 1,...

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021:   Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferred Shares 2016 7...

IPH Innate Pharma S... (Health Care)

Innate Pharma: 1 director

A director at Innate Pharma sold 10,000 shares at 5.500EUR and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Olga Smolentseva
  • Olga Smolentseva
IPH Innate Pharma S... (Health Care)

Update INNATE PHARMA BUY – TP EUR12 vs. 6.4 Monalizumab smiles again

Update INNATE PHARMA BUY – TP EUR12 vs. 6.4 Monalizumab smiles again Innate Pharma’s equity story received a significant boost of confidence on the back of ESMO 2021, with the presentation of its ANKET platform, but most remarkably – monalizumab’s success in combination with AstraZeneca’s anti-PD-L1, durvalumab (Imfinzi), as a maintenance therapy for stage III NSCLC. Recall, Monalizumab is being developed in collaboration with AZ and the amendment of the expected milestone payment left investors doubting AZ’s confidence in this programme. At ESMO 2021, AZ presented impressive interim res...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Number of Shares and Voting Rights of Innate Pharma as of September 1,...

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 MARSEILLE, France, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021: Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferred Shares 20...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er s...

Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er septembre 2021 Marseille, 23 sept. 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») publie le nombre d’actions composant son capital social ainsi que le nombre de droits de vote associés au 1er septembre 2021 :          Nombre d’actions composant le capital :79 294 402 actions ordinaires 6 784 Actions de Préférence 2016 ...

 PRESS RELEASE
IPH Innate Pharma S... (Health Care)

Number of Shares and Voting Rights of Innate Pharma as of September 1,...

Number of Shares and Voting Rights of Innate Pharma as of September 1, 2021 Marseille, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as at September 1, 2021:   Total number of shares outstanding:79,294,402 ordinary shares 6,784 Preferred Shares 2016 7...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch